Biosimilar filgrastim (Zarzio®) vs. lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience

Francesco Marchesi; Michele Vacca; Svitlana Gumenyuk; Annino Pandolfi; Daniela Renzi; Francesca Palombi; Francesco Pisani; Atelda Romano; Antonio Spadea; Francesco Ipsevich; S Santinelli; Mafalda De Rienzo; Elena Papa; Marco Canfora; L Laurenzi; Maria Laura Foddai; Luca Pierelli; Andrea Mengarelli

doi:10.3109/10428194.2015.1063147

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The combination of chemotherapy and granulocyte-colony stimulating factor (G-CSF) in patients with hematologic malignancies is considered the best regimen to mobilize peripheral blood hematopoietic...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Marchesi et al. (2015) studied this question.

synapsesocial.com/papers/6a8308f4191215dee0b37cd3 https://doi.org/10.3109/10428194.2015.1063147

View Full Paper

Ask AI

Bookmark

Share

Biosimilar filgrastim (Zarzio®) vs. lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience

Ask about this paper

Abstract

Discussion

Cite This Study

Biosimilar filgrastim (Zarzio®) vs. lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading